Last reviewed · How we verify

NCT05555394: BATBF

Body Awareness Therapy and Biomarkers in Fibromyalgia

Recruiting now NA Last updated 8 May 2025
What this trial tests

NA trial testing Basic Body Awareness Therapy in Fibromyalgia in 110 participants. Currently enrolling.

Timeline
8 May 2024
Primary endpoint
1 May 2025
1 September 2025

Quick facts

Lead sponsorUniversitat de Lleida
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment110
Start date8 May 2024
Primary completion1 May 2025
Estimated completion1 September 2025
Sites2 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Universitat de Lleida

Who can join

Adults 18 to 65, any sex, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized trial of Basic Body Awareness Therapy (BBAT) is applied in fibromyalgia patients as compared with a control intervention consisting of stretching. Sessions of BBAT lasted 90 min each and took place twice a week form 12 weeks. The primary end point is a change in the biomarkers and neurotransmitters and the Fibromyalgia Impact Questionnaire and the secondary end points include Visual Analog Scale, State Trait Anxiety inventory, Beck Depression Inventory. All assessments will be repeated at post treatment, 12 and 24 weeks and 1 year follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Basic Body Awareness Therapy

Trials testing the same drug.

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

Other Universitat de Lleida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05555394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing